ES2929058T3 - Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos - Google Patents

Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos Download PDF

Info

Publication number
ES2929058T3
ES2929058T3 ES16822054T ES16822054T ES2929058T3 ES 2929058 T3 ES2929058 T3 ES 2929058T3 ES 16822054 T ES16822054 T ES 16822054T ES 16822054 T ES16822054 T ES 16822054T ES 2929058 T3 ES2929058 T3 ES 2929058T3
Authority
ES
Spain
Prior art keywords
mrsa
pbp2a
composition
resistance
meropenem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16822054T
Other languages
English (en)
Spanish (es)
Inventor
Gautam Dantas
Patrick Gonzales
Kevin Forsberg
Mitchell Pesesky
Mayland Chang
Shahriar Mobashery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Notre Dame
Washington University in St Louis WUSTL
Original Assignee
University of Notre Dame
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Notre Dame, Washington University in St Louis WUSTL filed Critical University of Notre Dame
Application granted granted Critical
Publication of ES2929058T3 publication Critical patent/ES2929058T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES16822054T 2015-07-09 2016-07-08 Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos Active ES2929058T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190588P 2015-07-09 2015-07-09
PCT/US2016/041565 WO2017008034A1 (en) 2015-07-09 2016-07-08 Compositions and methods of use of antibacterial drug combinations

Publications (1)

Publication Number Publication Date
ES2929058T3 true ES2929058T3 (es) 2022-11-24

Family

ID=57686086

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16822054T Active ES2929058T3 (es) 2015-07-09 2016-07-08 Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos

Country Status (9)

Country Link
US (3) US10500191B2 (pl)
EP (2) EP3319609B1 (pl)
JP (3) JP6845511B2 (pl)
CN (2) CN108289896B (pl)
DK (1) DK3319609T3 (pl)
ES (1) ES2929058T3 (pl)
PL (1) PL3319609T3 (pl)
PT (1) PT3319609T (pl)
WO (1) WO2017008034A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6845511B2 (ja) 2015-07-09 2021-03-17 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 抗細菌性薬剤併用物の組成物及び使用方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
BR112020006658A2 (pt) 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas
US11690810B2 (en) * 2018-11-14 2023-07-04 The Chinese University Of Hong Kong Combination treatment of bacterial infection
CN110279692A (zh) * 2019-07-17 2019-09-27 中南大学湘雅二医院 一种抗感染组合物、制剂及其应用
GB202100378D0 (en) * 2021-01-12 2021-02-24 Quadram Inst Bioscience Methods and compositions for antibiotic potentiation
CN113559099A (zh) * 2021-08-27 2021-10-29 丹诺医药(苏州）有限公司 包含舒巴坦和阿维巴坦的药物组合物及其应用
WO2024010495A1 (ru) * 2022-07-05 2024-01-11 Сергей Владимирович СИДОРЕНКО Средство для лечения инфекций, вызванных множественно-устойчивыми бактериями
CN115778949A (zh) * 2022-12-15 2023-03-14 复旦大学附属华山医院 用于抑制产kpc酶肺炎克雷伯菌的组合物、药物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565456A (zh) * 2003-06-14 2005-01-19 张哲峰 一种头孢吡肟抗菌组合药物
CA2686348A1 (en) 2007-05-21 2008-11-27 Hans Rudolf Pfaendler Bactericidal anti-mrsa active pharmaceutical composition containing carbapenems
US20100197650A1 (en) * 2008-08-28 2010-08-05 Forest Laboratories Holdings Ltd. Compositions and methods of treatment comprising ceftaroline
CN102349897B (zh) * 2011-07-22 2012-12-26 深圳市新泰医药有限公司 一种美罗培南钠/他唑巴坦钠药物组合物
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013085152A1 (en) 2011-12-07 2013-06-13 Union Korea Pharm Co., Ltd. Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors
WO2014033561A1 (en) 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
GB201306980D0 (en) 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
CA2983992A1 (en) * 2015-04-30 2016-11-03 The Regents Of The University Of Colorado, A Body Corporate Polycyclic indoline and indolenine compounds
JP6845511B2 (ja) 2015-07-09 2021-03-17 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 抗細菌性薬剤併用物の組成物及び使用方法
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections

Also Published As

Publication number Publication date
JP2021075560A (ja) 2021-05-20
US20200054605A1 (en) 2020-02-20
US20230293488A1 (en) 2023-09-21
JP2022141948A (ja) 2022-09-29
EP3319609A4 (en) 2018-12-12
CN114796499A (zh) 2022-07-29
JP2018525434A (ja) 2018-09-06
US11559514B2 (en) 2023-01-24
US10500191B2 (en) 2019-12-10
EP3319609A1 (en) 2018-05-16
JP7121954B2 (ja) 2022-08-19
PL3319609T3 (pl) 2022-12-05
EP3319609B1 (en) 2022-06-15
CN108289896B (zh) 2022-03-01
PT3319609T (pt) 2022-08-23
DK3319609T3 (da) 2022-08-22
HK1258393A1 (zh) 2019-11-08
EP4112057A1 (en) 2023-01-04
WO2017008034A1 (en) 2017-01-12
US20180200226A1 (en) 2018-07-19
CN108289896A (zh) 2018-07-17
JP6845511B2 (ja) 2021-03-17

Similar Documents

Publication Publication Date Title
ES2929058T3 (es) Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos
US10376499B2 (en) Combination therapy for treatment of resistant bacterial infections
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
WO2017203266A1 (en) Combination therapy for treatment of resistant bacterial infections
Coleman Recent advances in the treatment of Gram-positive infections
ES2690725T3 (es) Composiciones que comprenden cefepima y tazobactam
CN106794250A (zh) 包含抗菌剂的药物组合物
WO2013066469A2 (en) Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics
HK1258393B (en) Compositions and methods of use of antibacterial drug combinations
US10772900B2 (en) Drug target for treating veterinary infections and methods of using same
Fratoni et al. Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii